Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leronlimab
- Development stage
- Phase 3
- Lead developer
- CytoDyn
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Leronlimab is a humanized IgG4 monoclonal antibody that targets the CCR5 receptor on T lymphocytes. It acts as a CCR5 antagonist and is being developed for multiple indications including HIV infection, metastatic triple-negative breast cancer (mTNBC), and other cancers. Leronlimab blocks the CCR5 receptor, preventing HIV from entering CD4+ cells and modulating immune responses. It has also been investigated for its potential to reduce inflammation in severe COVID-19 by mitigating cytokine storm effects. The drug was originally developed by Progenics Pharmaceuticals and is currently under development by CytoDyn with clinical trials ongoing or completed in several indications[1][2][3][4][5][6][7].
- Brand names
- Vyrologix
- Other names
- leronlimabPRO 140PRO140PRO-140
02
Targets
CCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on leronlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leronlimab.